322 related articles for article (PubMed ID: 32531754)
1. Covid-19 in a patient with multiple sclerosis treated with natalizumab: May the blockade of integrins have a protective role?
Aguirre C; Meca-Lallana V; Barrios-Blandino A; Del Río B; Vivancos J
Mult Scler Relat Disord; 2020 Sep; 44():102250. PubMed ID: 32531754
[TBL] [Abstract][Full Text] [Related]
2. Natalizumab: Perspectives from the Bench to Bedside.
Shirani A; Stüve O
Cold Spring Harb Perspect Med; 2018 Dec; 8(12):. PubMed ID: 29500304
[TBL] [Abstract][Full Text] [Related]
3. Upregulation of integrin expression on monocytes in multiple sclerosis patients treated with natalizumab.
Dallari S; Franciotta D; Carluccio S; Signorini L; Gastaldi M; Colombo E; Bergamaschi R; Elia F; Villani S; Ferrante P; Delbue S
J Neuroimmunol; 2015 Oct; 287():76-9. PubMed ID: 26439965
[TBL] [Abstract][Full Text] [Related]
4. Natalizumab for Multiple Sclerosis: A Case in Point for the Impact of Translational Neuroimmunology.
Shirani A; Stüve O
J Immunol; 2017 Feb; 198(4):1381-1386. PubMed ID: 28167648
[TBL] [Abstract][Full Text] [Related]
5. Disease-Modifying Therapies and Coronavirus Disease 2019 Severity in Multiple Sclerosis.
Sormani MP; De Rossi N; Schiavetti I; Carmisciano L; Cordioli C; Moiola L; Radaelli M; Immovilli P; Capobianco M; Trojano M; Zaratin P; Tedeschi G; Comi G; Battaglia MA; Patti F; Salvetti M;
Ann Neurol; 2021 Apr; 89(4):780-789. PubMed ID: 33480077
[TBL] [Abstract][Full Text] [Related]
6. Safety of disease-modifying treatments in SARS-CoV-2 antibody-positive multiple sclerosis patients.
Mallucci G; Zito A; Baldanti F; Gastaldi M; Fabbro BD; Franciotta D; Bergamaschi R
Mult Scler Relat Disord; 2021 Apr; 49():102754. PubMed ID: 33609958
[TBL] [Abstract][Full Text] [Related]
7. B-cell depleting therapies may affect susceptibility to acute respiratory illness among patients with multiple sclerosis during the early COVID-19 epidemic in Iran.
Safavi F; Nourbakhsh B; Azimi AR
Mult Scler Relat Disord; 2020 Aug; 43():102195. PubMed ID: 32460086
[TBL] [Abstract][Full Text] [Related]
8. Reversibility of the effects of natalizumab on peripheral immune cell dynamics in MS patients.
Plavina T; Muralidharan KK; Kuesters G; Mikol D; Evans K; Subramanyam M; Nestorov I; Chen Y; Dong Q; Ho PR; Amarante D; Adams A; De Sèze J; Fox R; Gold R; Jeffery D; Kappos L; Montalban X; Weinstock-Guttman B; Hartung HP; Cree BAC
Neurology; 2017 Oct; 89(15):1584-1593. PubMed ID: 28916537
[TBL] [Abstract][Full Text] [Related]
9. COVID-19 in 7 multiple sclerosis patients in treatment with ANTI-CD20 therapies.
Meca-Lallana V; Aguirre C; Beatrizdel Río ; Cardeñoso L; Alarcon T; Vivancos J
Mult Scler Relat Disord; 2020 Sep; 44():102306. PubMed ID: 32585617
[TBL] [Abstract][Full Text] [Related]
10. Impact of coronavirus disease (COVID-19) pandemic on multiple sclerosis care.
Salama S; Ahmed SF; Ibrahim Ismail I; Alroughani R
Clin Neurol Neurosurg; 2020 Oct; 197():106203. PubMed ID: 32919242
[No Abstract] [Full Text] [Related]
11. Melanoma complicating treatment with natalizumab for multiple sclerosis: A report from the Southern Network on Adverse Reactions (SONAR).
Sabol RA; Noxon V; Sartor O; Berger JR; Qureshi Z; Raisch DW; Norris LB; Yarnold PR; Georgantopoulos P; Hrushesky WJ; Bobolts L; Ray P; Lebby A; Kane RC; Bennett CL
Cancer Med; 2017 Jul; 6(7):1541-1551. PubMed ID: 28635055
[TBL] [Abstract][Full Text] [Related]
12. Establishment of a safety protocol for the administration of treatments in multiple sclerosis during the SARS-CoV-2 pandemic.
Meca-Lallana V; Aguirre C; Cardeñoso L; Alarcon T; Figuerola-Tejerina A; Del Río B; Álvarez MR; Vivancos J
Mult Scler Relat Disord; 2020 Sep; 44():102244. PubMed ID: 32544863
[No Abstract] [Full Text] [Related]
13. Treating patients with multiple sclerosis during the COVID-19 pandemic: Assessing the expert recommendations.
Guevara C; Villa E; Rosas CS; Diaz V; Naves R
Mult Scler Relat Disord; 2020 Aug; 43():102224. PubMed ID: 32464582
[No Abstract] [Full Text] [Related]
14. A Review on Clinical Pharmacokinetics, Pharmacodynamics, and Pharmacogenomics of Natalizumab: A Humanized Anti-α4 Integrin Monoclonal Antibody.
Li H; Shi FH; Huang SY; Zhang SG; Chen ML
Curr Drug Metab; 2018; 19(14):1213-1223. PubMed ID: 29708072
[TBL] [Abstract][Full Text] [Related]
15. Anti-natalizumab antibodies during 8 years of natalizumab treatment: effect on natalizumab concentration and α4-integrin receptor saturation.
van Kempen ZLE; van Rossum JA; Doesburg D; Claessen I; de Vries A; Ten Brinke A; van Oosten BW; Rispens T; Killestein J
J Neurol; 2019 Jul; 266(7):1804-1805. PubMed ID: 31004214
[No Abstract] [Full Text] [Related]
16. Safety of Natalizumab infusion in multiple sclerosis patients during active SARS-CoV-2 infection.
Landi D; Cola G; Mantero V; Balgera R; Moiola L; Nozzolillo A; Dattola V; Sinisi L; Fantozzi R; Di Lemme S; Centonze D; Mataluni G; Nicoletti CG; Marfia GA
Mult Scler Relat Disord; 2022 Jan; 57():103345. PubMed ID: 35158454
[TBL] [Abstract][Full Text] [Related]
17. COVID-19 occurring during Natalizumab treatment: a case report in a patient with extended interval dosing approach.
Borriello G; Ianniello A
Mult Scler Relat Disord; 2020 Jun; 41():102165. PubMed ID: 32388451
[TBL] [Abstract][Full Text] [Related]
18. Natalizumab therapy for highly active pediatric multiple sclerosis.
Kornek B; Aboul-Enein F; Rostasy K; Milos RI; Steiner I; Penzien J; Hellwig K; Pitarokoili K; Storm van's Gravesande K; Karenfort M; Blaschek A; Meyer A; Seidl R; Debelic D; Vass K; Prayer D; Kristoferitsch W; Bayas A
JAMA Neurol; 2013 Apr; 70(4):469-75. PubMed ID: 23420110
[TBL] [Abstract][Full Text] [Related]
19. The Matrix Metalloproteinases Panel in Multiple Sclerosis Patients Treated with Natalizumab: A Possible Answer to Natalizumab Non- Responders.
Balasa R; Bianca C; Septimiu V; Iunius S; Adina H; Sebastian A; Andreea R; Anca M; Smaranda M
CNS Neurol Disord Drug Targets; 2018; 17(6):464-472. PubMed ID: 29968546
[TBL] [Abstract][Full Text] [Related]
20. Rescue of severe brain and cervical cord IRIS by restarting natalizumab in a pregnant MS patient.
Massey TH; Smith R; Sadiq S; Overton C; Pearson OR
Neurology; 2017 Feb; 88(7):711-713. PubMed ID: 28077489
[No Abstract] [Full Text] [Related]
[Next] [New Search]
